Lurasidone: a new drug in development for schizophrenia (Q35005165)

5 August 2017

1 reference

title

Lurasidone: a new drug in development for schizophrenia (English)

1 reference

5 August 2017

0 references

1 reference

ChEBI release 2020-05-28

Jonathan M Meyer

1

1 reference

5 August 2017

Antony D Loebel

series ordinal

2

1 reference

5 August 2017

Edward Schweizer

series ordinal

3

1 reference

5 August 2017

language of work or name

English

0 references

publication date

1 November 2009

1 reference

Expert Opinion on Investigational Drugs

5 August 2017

published in

1 reference

5 August 2017

volume

18

1 reference

5 August 2017

issue

11

1 reference

5 August 2017

page(s)

1715-1726

1 reference

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543780903286388

The 'atypicality' of antipsychotics: a concept re-examined and re-defined

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903286388

Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903286388

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903286388

Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903286388

A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903286388

Which comes first: atypical antipsychotic treatment or cardiometabolic risk?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903286388

Cognition, drug treatment, and functional outcome in schizophrenia: a tale of two transitions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903286388

Negative symptoms of schizophrenia: a problem that will not go away

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903286388

Functional, molecular and pharmacological advances in 5-HT7 receptor research

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903286388

Effects of the 5-HT7 receptor antagonists SB-269970 and DR 4004 in autoshaping Pavlovian/instrumental learning task

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903286388

Genetic knockout and pharmacological blockade studies of the 5-HT7 receptor suggest therapeutic potential in depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903286388

5-HT7 receptor antagonists as a new class of antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903286388

Effects of SB-269970, a 5-HT7 receptor antagonist, in mouse models predictive of antipsychotic-like activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903286388

Inactivation of the 5-HT(7) receptor partially blocks phencyclidine-induced disruption of prepulse inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903286388

M4 agonists/5HT7 antagonists with potential as antischizophrenic drugs: serominic compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903286388

Cognitive dysfunction in neuropsychiatric disorders: selected serotonin receptor subtypes as therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903286388

Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903286388

Lurasidone reverses MK-801-induced impairment of learning and memory in the Morris water maze and radial-arm maze tests in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903286388

Relationship of cognition and psychopathology to functional impairment in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903286388

Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903286388

Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903286388

Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903286388

Schizophrenia: moving beyond monoamine antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903286388

Identification of separable cognitive factors in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903286388

Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903286388

Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903286388

Identifying cognitive mechanisms targeted for treatment development in schizophrenia: an overview of the first meeting of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia Initiative

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903286388

The pipeline and future of drug development in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903286388

Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903286388

Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903286388

The metabolic syndrome and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903286388

The evolution of drug development in schizophrenia: past issues and future opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903286388

10.1517/13543780903286388

21 January 2018

Identifiers

DOI

1 reference

5 August 2017

1 reference